To evaluate response to rozanolixizumab over multiple treatment cycles in patients with generalized myasthenia gravis (MG) based on response in Cycle 1.
No takes yet. Share an insight, caveat, or question.
Pascuzzi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: